Skip to Main Content
S. Karger AG
header search
Search
Advanced Search
Skip Nav Destination

Early Deferasirox Treatment in a Patient with Myelodysplastic Syndrome Results in a Long-Term Reduction in Transfusion Requirements

Acta Haematol (2009) 121 (1): 19–20.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Lower‐risk myelodysplastic syndromes: Current treatment options for anemia
  • Mathieu Meunier
  • Sophie Park
eJHaem (2022) 3 (4): 1091.
Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS
  • Heather A. Leitch
  • Rena Buckstein
  • Nancy Zhu
  • Thomas J. Nevill
  • Karen W.L. Yee
  • Brian Leber
  • Mary-Margaret Keating
  • Eve St. Hilaire
  • Rajat Kumar
  • Robert Delage
  • Michelle Geddes
  • John M. Storring
  • April Shamy
  • Mohamed Elemary
  • Richard A. Wells
Leukemia Research (2018) 74: 21.
Sustained Erythroid Response in a Patient with Myelofibrosis Receiving Concomitant Treatment with Ruxolitinib and Deferasirox
  • Eugenio Piro
  • Maria Lentini
  • Luciano Levato
  • Antonio Russo
  • Stefano Molica
Chemotherapy (2018) 63 (2): 107.
Reactive oxygen species levels control NF-κB activation by low dose deferasirox in erythroid progenitors of low risk myelodysplastic syndromes
  • Mathieu Meunier
  • Sarah Ancelet
  • Christine Lefebvre
  • Josiane Arnaud
  • Catherine Garrel
  • Mylène Pezet
  • Yan Wang
  • Patrice Faure
  • Gautier Szymanski
  • Nicolas Duployez
  • Claude Preudhomme
  • Denis Biard
  • Benoit Polack
  • Jean-Yves Cahn
  • Jean Marc Moulis
  • Sophie Park
Oncotarget (2017) 8 (62): 105510.
Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase
  • Roberto Latagliata
  • Chiara Montagna
  • Raffaele Porrini
  • Ambra Di Veroli
  • Sabrina Crescenzi Leonetti
  • Pasquale Niscola
  • Fabrizio Ciccone
  • Antonio Spadea
  • Massimo Breccia
  • Luca Maurillo
  • Angela Rago
  • Francesca Spirito
  • Michele Cedrone
  • Marianna De Muro
  • Marco Montanaro
  • Alessandro Andriani
  • Antonino Bagnato
  • Enrico Montefusco
  • Giuliana Alimena
European Journal of Haematology (2016) 96 (6): 643.
New insights into transfusion-related iron toxicity: Implications for the oncologist
  • John B. Porter
  • Theo de Witte
  • M. Domenica Cappellini
  • Norbert Gattermann
Critical Reviews in Oncology/Hematology (2016) 99: 261.
An increase in hemoglobin, platelets and white blood cells levels by iron chelation as single treatment in multitransfused patients with myelodysplastic syndromes: clinical evidences and possible biological mechanisms
  • Massimo Breccia
  • Maria Teresa Voso
  • Maria Antonietta Aloe Spiriti
  • Susanna Fenu
  • Luca Maurillo
  • Francesco Buccisano
  • Agostino Tafuri
  • Giuliana Alimena
Annals of Hematology (2015) 94 (5): 771.
Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy
  • Harpreet Kochhar
  • Chantal S. Leger
  • Heather A. Leitch
Case Reports in Hematology (2015) 2015: 1.
Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome
  • Niraj Shenoy
  • Nishanth Vallumsetla
  • Eliezer Rachmilewitz
  • Amit Verma
  • Yelena Ginzburg
Blood (2014) 124 (6): 873.
Review of therapeutic options and the management of patients with myelodysplastic syndromes
  • Mehmet A Özcan
  • Osman Ilhan
  • Osman I Ozcebe
  • Meliha Nalcaci
  • Zafer Gülbas
Expert Review of Hematology (2013) 6 (2): 165.
When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
  • David P. Steensma
  • Norbert Gattermann
Best Practice & Research Clinical Haematology (2013) 26 (4): 431.
Efficacy and safety of deferasirox in myelodysplastic syndromes
  • Massimo Breccia
  • Giuliana Alimena
Annals of Hematology (2013) 92 (7): 863.
Deferasirox treatment improved hematopoiesis and led to complete remission in a patient with pure red cell aplasia
  • Minoru Kojima
  • Shinichiro Machida
  • Ai Sato
  • Mitsuki Miyamoto
  • Makiko Moriuchi
  • Yoshiaki Ohbayashi
  • Kiyoshi Ando
International Journal of Hematology (2013) 98 (6): 719.
Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review
  • Roberto Guariglia
  • Maria Carmen Martorelli
  • Oreste Villani
  • Giuseppe Pietrantuono
  • Giovanna Mansueto
  • Fiorella D’Auria
  • Vitina Grieco
  • Gabriella Bianchino
  • Rosa Lerose
  • Giovanni Battista Bochicchio
  • Pellegrino Musto
Leukemia Research (2011) 35 (5): 566.
Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome
  • Maria L. H. Cuijpers
  • Reinier A. P. Raymakers
  • Marius A. MacKenzie
  • Theo J. M. de Witte
  • Dorine W. Swinkels
British Journal of Haematology (2010) 149 (3): 322.
Effect of iron chelator deferasirox on chronic anemia and thrombocytopenia in a transfusion-dependent patient with myelodysplastic syndrome
  • Takamasa Nishiuchi
  • Yuichi Okutani
  • Toshikazu Fujita
  • Kazuya Yoshida
  • Hiroaki Ohnishi
  • Reiji Haba
International Journal of Hematology (2010) 91 (2): 333.
Iron Chelation Therapy in Myelodysplastic Syndromes
  • Emanuela Messa
  • Daniela Cilloni
  • Giuseppe Saglio
Advances in Hematology (2010) 2010: 1.
  • Online ISSN 1421-9662
  • Print ISSN 0001-5792
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal